- Home
- CKPT vs ETON Comparison
CKPT vs ETON Comparison
Compare CKPT & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- ETON
- Stock Information
- Founded
- CKPT 2014
- ETON 2017
- Country
- CKPT United States
- ETON United States
- Employees
- CKPT N/A
- ETON N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- CKPT Health Care
- ETON Health Care
- Exchange
- CKPT Nasdaq
- ETON Nasdaq
- Market Cap
- CKPT N/A
- ETON 199.5M
- IPO Year
- CKPT 2017
- ETON 2018
- Fundamental
- Price
- CKPT $3.77
- ETON $8.82
- Analyst Decision
- CKPT Strong Buy
- ETON Strong Buy
- Analyst Count
- CKPT 2
- ETON 3
- Target Price
- CKPT $12.00
- ETON $12.00
- AVG Volume (30 Days)
- CKPT 946.5K
- ETON 214.1K
- Earning Date
- CKPT 11-11-2024
- ETON 11-11-2024
- Dividend Yield
- CKPT N/A
- ETON N/A
- EPS Growth
- CKPT N/A
- ETON N/A
- EPS
- CKPT N/A
- ETON N/A
- Revenue
- CKPT $78,000.00
- ETON $31,381,000.00
- Revenue This Year
- CKPT N/A
- ETON $19.61
- Revenue Next Year
- CKPT $151,162.55
- ETON $35.39
- P/E Ratio
- CKPT N/A
- ETON N/A
- Revenue Growth
- CKPT N/A
- ETON 8.14
- 52 Week Low
- CKPT $1.36
- ETON $3.03
- 52 Week High
- CKPT $3.95
- ETON $8.66
- Technical
- Relative Strength Index (RSI)
- CKPT 84.67
- ETON 76.07
- Support Level
- CKPT $2.37
- ETON $7.58
- Resistance Level
- CKPT $2.54
- ETON $8.66
- Average True Range (ATR)
- CKPT 0.27
- ETON 0.42
- MACD
- CKPT 0.10
- ETON -0.07
- Stochastic Oscillator
- CKPT 88.60
- ETON 91.49
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.